Barclays lowered the firm’s price target on Editas Medicine to $10 from $12 and keeps an Equal Weight rating on the shares. The company Q3 highlighted expectations for EDIT-301 Phase 1/2 RUBY in SCD and EdiTHAL in TDT at ASH 2023, with more patients and longer follow-up, the firm pointed out in a research note on Friday. As a lesson learned from exa-cel AdCom, Barclays would look for efficacy and off-target profile for potential differentiation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EDIT:
- Options Volatility and Implied Earnings Moves Today, November 03, 2023
- Editas Medicine Announces Third Quarter 2023 Results and Business Updates
- Editas Medicine reports Q3 EPS (55c), consensus (57c)
- Editas Medicine to present data from RUBY, EdiTHAL trials of EDIT-301
- Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar